Key Highlights
- Citadel expanded its Eli Lilly holdings by purchasing an additional 704,000 shares during Q2
- Griffin’s hedge fund now controls 945,000 LLY shares valued at $1.18 billion, ranking as the sixth-largest holding
- Shares have climbed 17% in 2025 and recently reached record levels
- The pharmaceutical giant rolled out Foundayo, its oral weight-loss medication, in the United Kingdom as Europe’s first market
- Analyst consensus points to Strong Buy with a price objective of $1,375.78
Shares of Eli Lilly are currently changing hands near $1,228, reflecting a 17% gain year-to-date, following a significant expansion of Ken Griffin’s Citadel position during the second quarter of 2026.
The hedge fund acquired 704,000 shares during the April-June period, pushing its total stake to 945,000 shares with a market value of $1.18 billion. This investment now represents Citadel’s sixth-most significant position among roughly 7,500 equity holdings.
Griffin’s timing appears strategic. Shares had declined 21% through April’s conclusion before staging a recovery. Citadel accumulated shares throughout the second quarter, and the pharmaceutical stock has rallied considerably in subsequent months.
The decline aligned with U.S. regulatory clearance for Foundayo, the company’s oral weight-loss medication. The stock subsequently rebounded and posted fresh all-time highs in recent trading sessions.
The company’s portfolio of weight-loss and diabetes treatments continues delivering robust performance. Revenue from these medications is projected to surpass $55 billion in the current fiscal year.
UK Market Entry for Foundayo
Eli Lilly introduced Foundayo to the United Kingdom market on Monday, establishing the UK as Europe’s inaugural market for the oral GLP-1 therapy. The medication, scientifically identified as orforglipron, is accessible through private prescriptions.
UK health authorities granted authorization for Foundayo on August 10. The drug represents the UK’s second tablet-form GLP-1 option, joining Novo Nordisk’s Wegovy pill.
British consumers can expect monthly costs ranging from Ā£100 to Ā£120 for Foundayo. This pricing undercuts the company’s injectable Mounjaro, which carries a Ā£330 monthly price tag.
By comparison, private market pricing for Wegovy tablets in the UK spans Ā£74 to Ā£129 monthly, varying by dosage strength and subscription arrangement.
NHS availability for Foundayo awaits completion of NICE’s evaluation process. The National Institute for Health and Care Excellence has requested additional data following initial committee deliberations, with no timeline established for subsequent assessment.
Analyst Sentiment on Eli Lilly
A total of twenty Wall Street analysts maintain coverage on LLY, delivering a consensus Strong Buy recommendation. This rating incorporates 18 Buy ratings alongside two Hold ratings published in the last three months.
The mean price objective stands at $1,375.78, suggesting approximately 12% appreciation potential from present trading levels.
European Union regulators continue evaluating Foundayo. Novo Nordisk’s Wegovy pill has secured a favorable assessment from the European Medicines Agency, though the European Commission’s final determination remains outstanding.
American consumers paying out-of-pocket for Foundayo face monthly costs beginning at $149 and extending to $349 for maximum dosages. A recently introduced Medicare pilot initiative provides limited availability at $50 monthly.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
